Gilead Sciences, Inc. (GILD) Shares Sold by First National Trust Co

Adjust Comment Print

The institutional investor held 8,677 shares of the health care company at the end of 2017Q3, valued at $703,000, down from 13,127 at the end of the previous reported quarter. Gmt Capital Corp who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $105.53B market cap company. The stock decreased 4.25% or $0.44 during the last trading session, reaching $9.91. About 4.21M shares traded. It has underperformed by 38.50% the S&P500.

Andrew Feldstein increased its stake in Torchmark Corp (TMK) by 194.52% based on its latest 2017Q3 regulatory filing with the SEC. Following the sale, the insider now owns 3,046,766 shares of the company's stock, valued at approximately $224,302,912.92. The hedge fund run by Panayotis Takis Sparaggis held 2.05M shares of the semiconductors company at the end of 2017Q3, valued at $184.29M, up from 2.04M at the end of the previous reported quarter. Avalon Global Asset Management Llc who had been investing in Gilead Sciences Inc for a number of months, seems to be less bullish one the $106.13B market cap company. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company's stock valued at $147,000 after purchasing an additional 1,613 shares during the last quarter. About 81,807 shares traded. It has outperformed by 16.59% the S&P500.

Analysts recommendation for Gilead Sciences, Inc. Therefore 59% are positive. Gilead Sciences had 124 analyst reports since July 29, 2015 according to SRatingsIntel. Of the 22 brokerages covering GILD, nine rate it a tepid "hold". Jefferies maintained the shares of GILD in report on Friday, October 27 with "Hold" rating. Mizuho has "Buy" rating and $95.0 target. SunTrust maintained Caesars Entertainment Corporation (NASDAQ:CZR) on Monday, February 5 with "Buy" rating. Leerink Swann maintained the stock with "Market Perform" rating in Wednesday, February 7 report. The rating was maintained by Piper Jaffray with "Hold" on Thursday, July 13. Barclays Capital maintained it with "Overweight" rating and $61 target in Monday, July 18 report.

Investors sentiment increased to 1.03 in Q3 2017. Its up 0.15, from 1 in 2017Q2. 72 funds opened positions while 223 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Credit Suisse maintained Gilead Sciences, Inc. (GILD) opened at $80.70 on Tuesday. Aviva Public Limited Liability holds 944,714 shares or 0.41% of its portfolio.

ITE Group's (LON:ITE) Reduce Rating Reaffirmed at Peel Hunt
RBC Capital Markets downgraded it to "Sector Performer" rating and GBX 135 target in Tuesday, December 19 report. The Spark Investment Management Llc holds 8,400 shares with $260,000 value, down from 24,500 last quarter.

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. (NASDAQ:GILD) for 7,191 shares. In the last ninety days, insiders sold 418,333 shares of company stock valued at $32,742,108. According to their observations and findings, the stock could provide a high EPS of $1.84/share and a low EPS of $1.36/share. Tiverton Asset Mgmt Ltd Liability Corp has 0.31% invested in Gilead Sciences, Inc. Howland Mgmt holds 1.72% or 256,501 shares in its portfolio. Appleton Prns Ma stated it has 23,147 shares or 0.32% of all its holdings. Moreover, Klingenstein Fields & Ltd Liability has 0.06% invested in Gilead Sciences, Inc. Stratos Wealth Ptnrs reported 17,421 shares. Royal Comml Bank Of Canada has invested 0.13% of its portfolio in Gilead Sciences, Inc. Schafer Cullen Mngmt owns 4,010 shares.

Since August 30, 2017, it had 0 buys, and 14 sales for $55.76 million activity. As per Monday, August 31, the company rating was upgraded by Zacks. $2.09M worth of Gilead Sciences, Inc. 25,000 shares were sold by Alton Gregg H, worth $2.07M. LLC boosted its position in shares of Gilead Sciences by 8.8% during the 2nd quarter. Boston Family Office Llc sold 3,870 shares as Gilead Sciences Inc (GILD)'s stock declined 8.05%. Shareholders of record on Friday, March 16th will be issued a dividend of $0.57 per share. (NASDAQ:GILD). Omers Administration Corp owns 37,800 shares or 0.03% of their United States portfolio. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company.

Stock has got OUTPERFORM rating from 2 analyst (s) whereas last month 2 analyst (s) have given outperform rating. Gilead Sciences presently has an average rating of "Buy" and a consensus price target of $87.04. The rating was downgraded by First Analysis on Thursday, January 26 to "Equal-Weight". Northern Trust Corporation holds 0% of its portfolio in Caesars Entertainment Corporation (NASDAQ:CZR) for 662,202 shares. The rating was maintained by Northland Capital on Thursday, June 29 with "Hold". The rating was maintained by Stephens with "Hold" on Wednesday, July 26. The firm earned "Neutral" rating on Monday, November 2 by Compass Point. Btg Pactual Global Asset Management Ltd sold 4,450 shares as the company's stock declined 8.05% while stock markets rallied. It also reduced its holding in Alphabet Inc by 380 shares in the quarter, leaving it with 7,300 shares, and cut its stake in General Electric Co (NYSE:GE).

Investors sentiment decreased to 1.04 in Q3 2017. Its down 0.15, from 0.88 in 2017Q2. Capital International Investors grew its position in shares of Gilead Sciences by 86.6% in the third quarter. (NASDAQ:UEPS) for 669,837 shares. Oppenheimer accumulated 1.00 million shares. Winfield Assoc accumulated 0.01% or 320 shares. Foster Motley stated it has 0.12% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: which released: "Does Gilead Stand A Chance After Its Q4 Earnings?" on February 08, 2018, also with their article: "The case for Gilead Sciences" published on January 21, 2018, published: "Is AbbVie or Gilead Sciences Stock a Better Buy?" on February 19, 2018. Patten & Patten Incorporated Tn reported 0.02% stake. Hap Trading, New York-based fund reported 73,795 shares.